Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Maria Zajac-Kaye"'
Autor:
Nair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, Nikhil Ponnoor Anto, Vijayasteltar B. Liju, Vijai V. Alex, Areekkara Nisthul Amrutha, Sreekumar U. Aiswarya, Mundanattu Swetha, Balachandran S. Vinod, Sankar Sundaram, Maria V. Guijarro, Thomas Herlevich, Archana Krishna, Nesteena K. Nestory, Smitha V. Bava, Chittalakkottu Sadasivan, Maria Zajac-Kaye, Ruby John Anto
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/03051782caec4638a50ea5fd81a0666a
Autor:
Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J. Kaye, Daohong Zhou
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-XL and MCL-1. Unfortun
Externí odkaz:
https://doaj.org/article/35172677c9ab498385ddea2d7bbcff21
Autor:
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Publikováno v:
Cells, Vol 13, Iss 6, p 528 (2024)
BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC). Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) induces dose-limiting thrombocytopenia through on-target BCL-xL inhibition in p
Externí odkaz:
https://doaj.org/article/a29e79df61604c65a48287af106a045c
Autor:
Maria V. Guijarro, Patrick C. Kellish, Peter E. Dib, Nicholas G. Paciaroni, Akbar Nawab, Jacob Andring, Lidia Kulemina, Nicholas V. Borrero, Carlos Modenutti, Michael Feely, Elham Nasri, Robert P. Seifert, Xiaoping Luo, Richard L. Bennett, Daniil Shabashvili, Jonathan D. Licht, Robert McKenna, Adrian Roitberg, Robert W. Huigens III, Frederic J. Kaye, Maria Zajac-Kaye
Publikováno v:
JCI Insight, Vol 8, Iss 10 (2023)
Although thymidylate synthase (TYMS) inhibitors have served as components of chemotherapy regimens, the currently available inhibitors induce TYMS overexpression or alter folate transport/metabolism feedback pathways that tumor cells exploit for drug
Externí odkaz:
https://doaj.org/article/880157298af5466e978ad20aa4f783da
Autor:
Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib an
Externí odkaz:
https://doaj.org/article/776b73003bc44789a62395d3ecb0ff21
Autor:
Vinod Vijayakurup, Kyungah Maeng, Hye Seung Lee, Benjamin Meyer, Sandra Burkett, Akbar Nawab, Michael W. Dougherty, Christian Jobin, Iqbal Mahmud, Timothy J. Garrett, Michael Feely, Kyoung Bun Lee, Frederic J. Kaye, Maria V. Guijarro, Maria Zajac-Kaye
Publikováno v:
JCI Insight, Vol 7, Iss 19 (2022)
Clinical studies of cancer patients have shown that overexpression or amplification of thymidylate synthase (TS) correlates with a worse clinical outcome. We previously showed that elevated TS exhibits properties of an oncogene and promotes pancreati
Externí odkaz:
https://doaj.org/article/c4d8ea92daf8429f8458305e8f8361ea
Autor:
Nair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, Nikhil Ponnoor Anto, Vijayasteltar B. Liju, Vijai V. Alex, Areekkara Nisthul Amrutha, Sreekumar U. Aiswarya, Mundanattu Swetha, Balachandran S. Vinod, Sankar Sundaram, Maria V. Guijarro, Thomas Herlevich, Archana Krishna, Nesteena K. Nestory, Smitha V. Bava, Chittalakkottu Sadasivan, Maria Zajac-Kaye, Ruby John Anto
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe ongoing treatment modalities for breast cancer (BC) primarily rely on the expression status of ER, PR and HER-2 receptors in BC tissues. Our strategy of chemosensitization provides new insights to counter chemoresistance, a major obstac
Externí odkaz:
https://doaj.org/article/98aa0d851ca44ca187bf9bcc4a9ba983
Autor:
Maria V. Guijarro, Akbar Nawab, Peter Dib, Sandra Burkett, Xiaoping Luo, Michael Feely, Elham Nasri, Robert P. Seifert, Frederic J. Kaye, Maria Zajac-Kaye
Publikováno v:
Oncogene.
We previously showed that elevated TYMS exhibits oncogenic properties and promotes tumorigenesis after a long latency, suggesting cooperation with sequential somatic mutations. Here we report the cooperation of ectopic expression of human TYMS with l
Autor:
Maria Zajac-Kaye, Patricia Steeg, Victor E. Marquez, Steven N. Hochwald, Frederic J. Kaye, Kent W. Hunter, Melinda Hollingshead, Kevin D. Brown, Lisa M. Dyer, Sherry X. Yang, Akbar Nawab, Daniel Shabashvili, Min Chen
PDF file - 235K, mRNA expression levels in normal mammary glands, mammary tumors and tumors from zebularine treated mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d6dd3a0549c4872ceb4ecc0c51937f4
https://doi.org/10.1158/1535-7163.22498743
https://doi.org/10.1158/1535-7163.22498743
Autor:
Maria Zajac-Kaye, Patricia Steeg, Victor E. Marquez, Steven N. Hochwald, Frederic J. Kaye, Kent W. Hunter, Melinda Hollingshead, Kevin D. Brown, Lisa M. Dyer, Sherry X. Yang, Akbar Nawab, Daniel Shabashvili, Min Chen
PDF file - 335K, Differentially down-regulated genes (>1.5-fold differences; P < 0.05) from mammary tumors of the PyMT transgenic mice exposed to zebularine for 48 days.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d6ec7089af8890cc4aa438aad93b67f
https://doi.org/10.1158/1535-7163.22498746
https://doi.org/10.1158/1535-7163.22498746